One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment

被引：0
|
作者：
Bunck, M. C. [1 ]
Mari, A. [2 ]
Corner, A. [3 ]
Eliasson, B. [4 ]
Shaginian, R. M. [5 ]
Wu, Y. [6 ]
Yan, P. [6 ]
Heine, R. J. [1 ,7 ]
Smith, U. [4 ]
Taskinen, M. -R. [3 ]
Yki-Jarvinen, H. [3 ]
Diamant, M. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Ctr Diabet, Amsterdam, Netherlands
[2] Inst Biomed Engn, Padua, Italy
[3] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland
[4] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden
[5] Eli Lilly & Co, Houten, Netherlands
[6] Amylin Pharmaceut Inc, San Diego, CA USA
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] Effect of one year of treatment with exenatide in a group of obese type 2 diabetic patients
    Buysschaert, M.
    Derdelinckx, L.
    Duvivier, E.
    Ippersiel, V.
    Leonet, J.
    Oriot, P.
    Paris, I.
    Preumont, V.
    Scarniere, D.
    Warnotte, C. V.
    DIABETES & METABOLISM, 2010, 36 : A79 - A79
  • [22] Progressive reductions in body weight with 82 weeks of exenatide treatment in overweight patients with type 2 diabetes
    Blonde, L
    Zhang, B
    Mac, S
    Poon, T
    Taylor, K
    Kim, D
    OBESITY RESEARCH, 2005, 13 : A26 - A26
  • [23] Exenatide plus metformin and glibenclamide compared with metformin plus glibenclamide on beta cell and alpha cell function and adipocytokines in patients with type 2 diabetes
    Koteshkova, O.
    Antsiferov, M.
    DIABETOLOGIA, 2016, 59 : S378 - S378
  • [24] Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)
    Dejager, Sylvie
    Lebeaut, Alexandre
    Couturier, Andre
    Schweizer, Anja
    DIABETES, 2006, 55 : A29 - A29
  • [25] Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial
    van Raalte, Daniel H.
    Bunck, Mathijs C.
    Smits, Mark M.
    Hoekstra, T.
    Corner, Anja
    Diamant, Michaela
    Eliasson, Bjorn
    Marja-RiittaTaskinen
    Heine, Robert J.
    Smith, Ulf
    Yki-Jarvinen, Hannele
    Mari, Andrea
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 175 (04) : 345 - 352
  • [26] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    Kendall, DM
    Riddle, MC
    Rosenstock, J
    Zhuang, DL
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETES CARE, 2005, 28 (05) : 1083 - 1091
  • [27] Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine
    Secnik, K
    Hayes, C
    Matza, L
    Kim, S
    Oglesby, A
    Yurgin, N
    Brodows, R
    Malley, K
    VALUE IN HEALTH, 2005, 8 (06) : A155 - A156
  • [28] Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus
    Rashid, Maryam
    Shahzad, Muhammad
    Mahmood, Saqib
    Khan, Khurshid
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (01) : 71 - 76
  • [29] Canagliflozin Treatment Improves Beta Cell Function in Subjects with Type 2 Diabetes
    Polidori, David
    Zhao, Yue
    Sha, Sue
    Canovatchel, William
    DIABETES, 2010, 59 : A176 - A176
  • [30] Beta cell function and glycaemic control following one year exenatide therapy, and after 12 week wash-out, in patients with type 2 diabetes
    Corner, A.
    Bunck, M. C.
    Diamant, M.
    Eliasson, B.
    Malloy, J. L.
    Shaginian, R. M.
    Deng, W.
    Kendall, D. M.
    Taskinen, M. R.
    Smith, U.
    Yki-Jarvinen, H.
    Heine, R. J.
    DIABETOLOGIA, 2008, 51 : S351 - S351
12345